By assessing the effects of β-catenin nuclear accumulation, they suggested that wogonoside prevented β-catenin translocation to the nucleus and downregulated its binding to T-cell factor/lymphoid enhancer-binding factor (TCF/Lef), the major effector of the Wnt/β-catenin signaling pathway, which ultimately inhibited the activation of target genes such as VEGF to halt angiogenesis in breast cancer [79]. This evidence concerns the gene VEGFA and breast cancer.